US stem cell clinics, patient safety, and the FDA

Research output: Contribution to journalComment/debate

40 Scopus citations

Abstract

Scholarship on patients accessing unproven stem cell interventions is dominated by research addressing 'stem cell tourism' to such countries as China, India, Mexico, and the Ukraine. However, clinics marketing 'adipose-derived mesenchymal stem cell treatments' are proliferating across the USA. These businesses typically claim to operate in compliance with federal regulations, but careful review of their commercial practices suggests that such clinics are marketing unapproved and noncompliant biological drugs.

Original languageEnglish (US)
Pages (from-to)271-273
Number of pages3
JournalTrends in Molecular Medicine
Volume21
Issue number5
DOIs
StatePublished - May 1 2015

Keywords

  • FDA
  • Federal regulations
  • Marketing
  • Stem cell clinics
  • United States

Fingerprint Dive into the research topics of 'US stem cell clinics, patient safety, and the FDA'. Together they form a unique fingerprint.

  • Cite this